Evidence map›Paper›PMID 39636331›Full record

ArticleInternational journal of hematology2025

Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.

Feng Chen, Shi Qiu, Ailing Gui, Shiyu Jiang, Yichen Yan, Jichuan Wu, Guangliang Chen, Shun Zhu, Yizhen Liu, Zuguang Xia and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Feng Chen *Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Shi Qiu *Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Ailing Gui *Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Shiyu JiangDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yichen YanDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Jichuan WuCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Guangliang ChenDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shun ZhuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Yizhen LiuDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zuguang XiaDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Baohua YuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaojian SunShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Juan Jennifer GuDepartment of Medicine & Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lan WangCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Wen LiuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Ling YangDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Qunling ZhangDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ji ZuoDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. jzuo@shmu.edu.cn.

Funding

Institutional Review Board of the Fudan University Shanghai Cancer Center, Shanghai, China 050432-4-1212BNational Natural Science Foundation of China 81670177National Natural Science Foundation of China 81773203National Natural Science Foundation of China 81970182National Natural Science Foundation of China 82060041
6 · The paper itself

Abstract

Peripheral T cell lymphoma (PTCL) is an aggressive and highly heterogeneous lymphoma with a bleak prognosis, highlighting the urgent need for an effective biomarker to guide therapeutic strategies. Ovarian tumor domain-containing 7B (OTUD7B) has been shown to have a critical function in the progression of cancers. However, the prognostic significance of OTUD7B in PTCL remains unexplored. In this study, we demonstrated for the first time that PTCL patients with low expression of OTUD7B had shorter progression-free survival (PFS) and overall survival (OS). In addition, OTUD7B knockdown promoted chemoresistance to doxorubicin in PTCL cell lines, and led to increased translocation of p52 from the cytoplasm to the nucleus. Inhibition of non-canonical NF-κB partially restored the sensitivity of PTCL cells to doxorubicin. Remarkably, 5-azacytidine and cytarabine upregulated the expression of OTUD7B and exhibited a synergistic anti-lymphoma effect in PTCL. In summary, our study confirmed the prognostic role of OTUD7B in PTCL and the promising therapeutic potential of combining 5-azacytidine or cytarabine and doxorubicin for PTCL treatment.

Indexed as

Gene Expression Regulation, NeoplasticLymphoma, T-Cell, PeripheralNF-kappa BCell Line, TumorDoxorubicinDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedPrognosisDoxorubicinNF-kappa BNon-canonical NF-κBOTUD7BPTCL

Identifiers

PMID39636331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.